For Payers

We are committed to ensuring that appropriate patients have uninterrupted access to gammaCore.

Published coverage support

The safety and efficacy of gammaCore have been established through our clinical development program, and additional analyses and studies provide economic evidence to support coverage for gammaCore.

Cost-Effectiveness of gammaCore (Non-Invasive Vagus Nerve Stimulation) for Acute Treatment of Episodic Cluster Headache:

gammaCore significantly adds economic value for the acute treatment of episodic attacks of cluster headaches, and findings of this analysis serve as additional robust economic evidence to support the need to modify current treatment guidelines and coverage policies.


Real-World Health Plan Claims Analysis of Differences in Healthcare Utilization and Total Cost in Patients Suffering From Cluster Headaches and Those Without Headache-Related Conditions:

There is a need for new treatment modalities in patients with cluster headaches, and more effective interventions and proper management, along with earlier diagnosis, may lead to improved patient outcomes and contained associated healthcare costs.


Qualitative Review of Non-Invasive Vagus Nerve Stimulation (gammaCore): Current Evidence on Efficacy, Safety and Economic Burden for Episodic and Chronic Cluster Headache:

Sufficient evidence exists to support the need to modify current reimbursement policies to differentiate non-invasive vagus nerve stimulation from invasive (implantable) vagus nerve stimulation and to explicitly include coverage for gammaCore (nVNS) for episodic cluster headache.


The Emerging Role of gammaCore® in the Management of Cluster Headache: Expert Panel Recommendations:

Panel recommendation that treatment guidelines should be updated to reflect the role of gammaCore as a first-line, acute treatment option for patients with episodic cluster headache, and that payers should offer coverage of gammaCore® to their members who have a diagnosis of episodic cluster headache.


Mechanism of Action of Non-Invasive Cervical Vagus Nerve Stimulation for the Treatment of Primary Headaches:

Non-invasive stimulation of the cervical branch of the vagus nerve may significantly expand the clinical use of vagus nerve stimulation, and preliminary clinical studies of non-invasive cervical vagus nerve stimulation in various primary headache disorders are encouraging.


gammaCore™ (non-invasive vagus nerve stimulator) is indicated for use in adult patients for the preventive treatment of cluster headache, the acute treatment of pain associated with episodic cluster headache, and the acute and preventive treatment of migraine in adolescent (age 12 and older) and adult patients.

Please see Important Safety Information. Please also see the gammaCore Instructions for Use.

nVNS therapy

Vagus nerve stimulation is a breakthrough technology that helps control multiple disorders.

Our product

gammaCore has become an answer for many people suffering from multiple disorders.